[Image: masthead]

24-HOUR MH HOTLINE

800-644-9737

FOR EMERGENCIES ONLY

24-HOUR MH HOTLINE: 800-644-9737
FOR EMERGENCIES ONLY

Blog

Blog

Regular updates by our President, MHAUS staff, and guest contributors.

New Laboratory to Offer Genetic Testing for MH Susceptibility and Related Disorders
Dr. Geogirene Vladutiu, PhD
December 8, 2015
Genetic testing for susceptibility to Malignant Hyperthermia is already offered by a number of commercial laboratories (see the MHAUS web site for details). A new laboratory, the Robert Guthrie Biochemical and Molecular Genetics Laboratory at Buffalo General Medical Center, Buffalo, New York is now offering genetic testing for MH …
Comments (0)
New drug holds potential to reduce the use of a potent MH trigger drug
Dr. Henry Rosenberg MD, CPE
November 16, 2015
Succinylcholine (Anectine) is an MH trigger. Generally injected intravenously, the drug is usually used to produce deep muscle relaxation in order to facilitate such procedures as intubation of the trachea. The onset of relaxation is very rapid and the duration is generally less than 10 minutes. Succinylcholine, introduced in the …
Comments (0)
Henry Rosenberg, M.D., Named 2014 DSA Recipient
MHAUS Staff
September 21, 2015
Please read this wonderful article about Dr. Rosenberg, the President of MHAUS. Dr. Rosenberg is receiving an award this year at the American Society of Anethesiologists Annual Meeting. Join MHAUS in honoring Dr. Henry Rosenberg as he receives the ASA's Distinguished Service Award on October 24, 2015 in San Diego, …
Comments (2)
My Graduate Student Experience with the Nurse Anesthesia Program at UP
Guest Contributor
September 9, 2015
My name is Brooke DiIanni and I am a graduate student in the nurse anesthesia program at the University Pittsburgh.  As part of our didactic curriculum we are afforded the opportunity to work side by side with a researcher and become personally involved with a research entity. Malignant Hyperthermia (MH) …
Comments (1)
A Summary of a SRNA's Summer at the NAMHR of MHAUS
Guest Contributor
September 9, 2015
As an undergraduate, I participated as a research assistant for a study on dementia. It was mostly data entry and busy work. When we were told we had to volunteer for a research project as part of our research practicum, I thought it would be more data entry. A classmate …
Comments (0)
Report on the 34th Annual European MH Group meeting, June 10-12, 2015
Dr. Henry Rosenberg MD, CPE
June 29, 2015
The annual meeting of the European MH group took place in the charming city of Lille, France. About 80 physicians, scientists, students and clinicians who are studying the problem of malignant hyperthermia attended, giving 41 presentations. Attendees came from many countries inside and outside Europe including the Soviet Union, South …
Comments (1)
Ryanodine Receptor-1 (RYR1)Related Myopathy Research Study, 15-NR-0072 Volunteers Needed
Guest Contributor
May 22, 2015
The National Institute of Nursing Research (NINR) at the National Institutes of Health (NIH) in Bethesda, Maryland, is conducting a research study to determine if a drug that has been approved by the FDA for other indications reduces the severity of some symptoms in people with ryanodine receptor 1-related myopathy …
Comments (0)
The use of emergency medical cooling system pads in the treatment of Malignant Hyperthermia
Guest Contributor
May 11, 2015
Hendrik L. Dhaese", Patrick R. Martens8, Nicolas H. Miiller8, Isabelle M. Casier", Jan Paul J. Muliera and Luc Heytensb aDepartment of Anesthesiology, Intensive Care and Emergency Medicine, AZ Sint-Jan Brugge-Oostende AV, Campus Brugge, Brugge and "Universiteit Antwerpen, Campus Drie Eiken, Universiteitsplein 1, Wilrijk, Belgium Correspondence to Hendrik Dhaese, MD, Department …
Comments (1)
Update on Dantrolene in the Treatment of Anesthetic Induced MH
Dr. Henry Rosenberg MD, CPE
April 20, 2015
Adverse Metabolic/Muscular Reaction to Anesthesia Reports (AMRAs) received after January 1, 2007 and before December 31, 2013 in the North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States were examined with the goal of describing any changes in the administration of dantrolene, complications associated with …
Comments (0)
MHAUS President’s Challenge Nearly Met!
Dianne Daugherty, MHAUS Executive Director
February 3, 2015
Were you interested to know the results of the MHAUS President’s Challenge issued toward the end of November 2014 and was open through December 25, 2014 The challenge was ALMOST met completely!  We received donations equaling about 90% of the challenge, or $4,480.  Thus, the total amount received will be …
Comments (0)
Fiscal Year 2013-2014 Year End Review
Dr. Henry Rosenberg MD, CPE
December 31, 2014
As the calendar year comes to a close, I would like to take a few minutes of your time to highlight some of the activities and programs that MHAUS has either introduced or amplified over the past year and point out some of the scientific advances related to MH and …
Comments (0)
Remarks made at the MHAUS reception, December 14, 2014
MHAUS Staff
December 29, 2014
I would like to welcome you to the first MHAUS reception at the NY Post Graduate Assembly. Thank you all for coming. Particular thanks go to Eagle Pharmaceuticals, the company that developed and introduced Ryanodex, a new formulation of dantrolene introduced into clinical practice this past summer which is perhaps …
Comments (0)
Recommendation for Temperature Monitoring during General Anesthesia
MHAUS Staff
November 26, 2014
Recommendation: MHAUS recommends core temperature monitoring for all patients given general anesthesia lasting more than 30 minutes. Appropriate sites for continuous electronic core temperature monitoring include the esophagus, nasopharynx, tympanic membrane (with probe in contact with the membrane), bladder, and the pulmonary artery. Background: Malignant hyperthermia (MH) is an inherited …
Comments (0)
Advances in Diagnostic Molecular Genetics and the Implications for Malignant Hyperthermia
Dr. Henry Rosenberg MD, CPE
August 26, 2014
Very recently, the Institute of Medicine, an independent, nonprofit, non-governmental prestigious "think tank" composed of eminent scholars published the proceedings of a roundtable discussion on "Translating Genomic-Based Research for Health".  In other words, "How do physicians and scientists make sense of the large amount of information that is derived from …
Comments (0)
Rare Disorder Roadmap to Testing Options and Answers
Dianne Daugherty, MHAUS Executive Director
August 5, 2014

Although malignant hyperthermia (MH) is an uncommon disorder, when it happens to you or your family member, it becomes a frequent and common topic of concern and animated conversation.

Thus, when one of our family members requested the Malignant Hyperthermia Association of the United States (MHAUS) develop a resource to begin to answer questions that regularly rose to the forefront when a family is given an unexpected diagnosis of malignant hyperthermia .  As this diagnosis could come from within the patient’s immediate family or their extended family members, the basic question seemed to remain the same, "I have been told I have malignant hyperthermia – now what does that mean for my life?" 

MHAUS felt this was a very important and recurring area of concern not only for the MH-susceptible individual, but also for their healthcare providers across many disciplines.  To address this need, in mid-September 2013, we gathered a group of dedicated individuals from both the healthcare professional and the patient side to work together on the project we called "MH Genetics 101".  The group contained MHAUS staff, a genetic counselor who was also an MH-susceptible individual, a parent who tragically lost his child to MH, personnel from one of the genetic testing centers and one of their genetic counselors, as well as a board member who happens to be a genetic expert and is known worldwide.  Additionally, the final document went through a number of iterations after receiving input and perspective from MHAUS Professional Advisory Council members and other MH experts.

Comments (1)
European MH Group Meeting Blog
Dr. Henry Rosenberg MD, CPE
June 16, 2014
May 15-17, 2014 The European MH Group consisting of clinicians and scientists interested in and studying MH and related disorders met in the beautiful town of Wurzburg, Germany, in the northern part of Bavaria. Wurzburg was the home of Dr. Wilhelm Conrad Roentgen, who discovered x-rays and was the first …
Comments (0)
The Malignant Hyperthermia Registry from an SRNA’s Point of View
Guest Contributor
May 16, 2014
I am currently a second year nurse anesthesia student at the University of Pittsburgh who had a wonderful opportunity to work alongside some of the most dedicated professionals I have ever met. I spent approximately 60 hours assisting at the North American Malignant Hyperthermia Registry (NAMHR) in Pittsburgh, PA as …
Comments (0)
Far Reaching New Information Concerning the Diagnosis and Management of MH and Exertional Heat Stroke
Dr. Henry Rosenberg MD, CPE
March 20, 2014
I believe that it is now safe to conclude that a significant percent of patients who experience heat stroke are MH susceptible according to the testing procedures currently available. One of the implications of this finding bears on the new formulation of dantrolene.
Comments (6)
What does it take to educate people about Malignant Hyperthermia (MH)?
Sharon J. Hirshey Dirksen, Ph.D.
June 20, 2013
It is hard to believe that a year has passed since I stopped working for MHAUS and started to teach writing at the college level. So, when I was invited to write a blog about my experience working for MHAUS as Scientific Officer (from 2007-2012), I thought, that might be …
Comments (7)
My Time at the North American Malignant Hyperthermia Registry: A Student Nurse Anesthestist’s Perspective
Valerie Pomerantz RN, BSN
May 14, 2013
I recently had the opportunity to participate at the North American Malignant Hyperthermia Registry (NAMHR) as part of my Research Practicum course at the University of Pittsburgh Nurse Anesthesia Program.
Comments (2)
The mission of MHAUS is to promote optimum care and
scientific understanding of MH and related disorders.